Compare DUOT & GALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DUOT | GALT |
|---|---|---|
| Founded | 1990 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.3M | 199.2M |
| IPO Year | 2017 | 2008 |
| Metric | DUOT | GALT |
|---|---|---|
| Price | $12.14 | $2.51 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | ★ $17.00 | $8.50 |
| AVG Volume (30 Days) | ★ 555.9K | 277.6K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.96 | 36.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $27,023,651.00 | N/A |
| Revenue This Year | $50.98 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 271.16 | N/A |
| 52 Week Low | $5.78 | $1.22 |
| 52 Week High | $12.17 | $7.13 |
| Indicator | DUOT | GALT |
|---|---|---|
| Relative Strength Index (RSI) | 77.38 | 56.58 |
| Support Level | $7.69 | $2.10 |
| Resistance Level | N/A | $2.60 |
| Average True Range (ATR) | 0.79 | 0.18 |
| MACD | 0.28 | 0.05 |
| Stochastic Oscillator | 100.00 | 77.70 |
Duos Technologies Group Inc delivers AI-driven technologies, edge computing infrastructure, and energy consulting services to support data-intensive and mission-critical operations. It manages, operates, engineers, software development, customer support and project implementation and management across three market segments, including rail technology deployment, Data Center co-location facilities, and behind-the-meter electrical power provision. It also continues to operate as a technology company which designs, develops, deploys, and operates intelligent technology solutions with a focus on software applications and artificial intelligence (AI) in addition to large projects, consulting, implementation, and asset management.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.